FSCN1 and esophageal squamous cell carcinoma: Such sensitivity is better than the recently identified autoantibody biomarkers in early-stage ESCC reported by our team, including autoantibodies against ezrin, fascin, and L1CAM [23, 34, 35], which indicates that autoantibodies against STIP1 might be an encouraging candidate for establishment of an optimized autoantibody signature required to gain high sensitivity necessary for ESCC screening.